Novel Diagnosis and Treatment Approaches in Pancreatic Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 July 2025 | Viewed by 12
Special Issue Editor
Interests: molecular mechanisms of pancreatic diseases; pancreatic fibrosis; biomarkers; genetics of pancreatic diseases; epidemiology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Pancreatic cancer still remains intractable due to difficulty in early diagnosis, its rapid progression, and its resistance to conventional therapy. To overcome these difficulties, multidisciplinary approaches including the development of novel diagnosis and treatment approaches are urgently needed. Recently, we have seen progress in the early diagnosis of pancreatic cancer such as the risk-factor stratification of new-onset diabetes mellitus, the development of microRNA-based biomarkers and cell-free DNA, and the identification of rather specific imaging findings. Regarding treatments, the efficacy of neoadjuvant chemotherapy has been proven, drugs that disrupt the tumor–stromal compartment might be useful for improved drug delivery, and targeted agents based on genetic testing such as PARP inhibitors for BRCA pathway-deficient pancreatic cancer and immune checkpoint inhibitors have shown promising results.
In this Special Issue, we will share up-to-date research findings in this field. Articles dealing with a wide range of novel diagnosis and treatment approaches in pancreatic cancer are welcome. Examples include, but are not limited to, the early diagnosis of pancreatic cancer based on risk factors, novel biomarkers, and imaging modalities including artificial intelligence. Basic, translational, and clinical research papers are all welcome.
Prof. Dr. Atsushi Masamune
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pancreatic cancer
- pancreatic fibrosis
- biomarker
- risk factor
- genetic testing
- artificial intelligence
- endoscopic ultrasound
- stroma
- cancer-associated fibroblasts
- familial pancreatic cancer
